2025 Poster Presentations
Preliminary List as of August 20
5 Prime Sciences, Inc.
From Genetic Insight to Phase 2b in Under 2 years: The 5Prime × Marea Story
AbCellera
Strategies for Tailoring T-Cell Engager Design for Solid Tumor Indications
Adimab LLC
Engineering a Panel of Potent and Developable Anti-CD3 Antibodies for Conditional Activation in the Tumor Microenvironment
Ardigen
Safer pHLA-Targeted Immunotherapies Through AI and Computational Immunology
AstraZeneca
Higher Throughput Proteomics Screens for Degrader Selectivity Profiling
AstraZeneca
Leveraging Virus-Like Particle (VLP) Technology for Antibody Discovery Against Complex Membrane Protein Targets Through In Vitro Display
Axxam
Differential Scanning Fluorimetry Screening and Biophysical Assays Identify Novel Small Molecule Binders of Pre-miR-21
Axxam
Precision Screening for Neurodegeneration: HiBiT Assay and Gene Expression in Action
Biosensing Instrument
Characterizing Binding Affinity and Avidity of Anti-HER1, Anti-HER2 and Anti-HER3 Therapeutic Antibodies in Whole Single Cells Using Label-Free Surface Plasmon Resonance Microscopy (SPRM)
BPS Bioscience, Inc.
Development of ATPase and Helicase Assays for DHX9, BLM, and WRN-Targeted Drug Discovery
BPS Bioscience, Inc.
From GLP-1 to Amylin: Development of Reporter Cell Lines for Next-Generation Metabolic Therapeutics
Bristol Myers Squibb
Implementation of Synthetic Antibody Libraries for Biotherapeutic Discovery
Carterra
Massively Parallel SPR-Based Fragment Screening of Kinase Arrays
Carterra
Selectivity and Cooperativity of PROTAC®s Using HT-SPR
Cayman Chemical Company
Fragment-Based Drug Discovery (FBDD) Approach for IRAK4
CDI Labs, Inc.
Molecular Glue/PROTAC Target ID Using HuProt Human Proteome Arrays
ChemPartner
A Novel In Vitro Platform for Evaluating Molecular Glue Degraders: Targeting VAV1 to Modulate Immune Signaling
ChemPartner
Advancing Drug Discovery Through Cytokine–Cytokine Receptor Interaction Platform
ChemPartner
Develop the Toolbox for Targeted Protein Degradation (TPD)-Based Drug Discovery
Chemspace
Approaches to Efficient Exploration of Large Combinatorial Spaces
Chemspace
Generation of Custom Synthetically Accessible Combinatorial Chemical Spaces Using Machine Learning-Based Reagent Filtering – Design of Freedom Space 4.0
Clarivate
Degraders on Target: Evaluating the Potential of this Novel Drug Class
Concept Life Sciences
Concept’s Direct to Biology (D2B) Approach to PROTAC Drug Discovery - A Streamlined Workflow for Innovative Fast Tracking of PROTACs
Concept Life Sciences
Introducing BioPALS – A Versatile Hit Identification Technology Powered by AI and Enabled by GCI
Conigen Bioscience
GPCR PAR1 or DRD2-Specific Monoclonal Antibodies Can Detect the Target Expressed on Live Cell Surfaces by Flow Cytometry
Conigen Bioscience
Recombinant Bioactive CXCR4 or CXCR5 on Virus-Like Nanoparticles Can Bind to Their Chemokine Ligand CXCL12 or CXCL13
Cube Biotech GmbH
A New Era for Full-Length Membrane Targets: From Lysate to Structure- and Assay-Ready Protein in 45 Minutes
Dalriada Drug Discovery, Inc.
iCLASS: Live-Cell Ligand Discovery Platform for “Hard-to-Drug” Protein Targets
DEL Source
Accelerating Covalent Drug Discovery with AI and Warhead Diversity for Challenging Targets
DEL Source
Enabling Hit Discovery with DEL-Pilot, Off-the-Shelf Libraries, Custom Synthesis, and Bespoke Library Pools
Domainex Ltd.
Accelerated Covalent Fragment Hit Discovery for KRAS [G12C] Using Mass Spectrometry and Direct-to-Biology Screening
Domainex Ltd.
Molecular Matchmakers: Finding the Perfect Glue
Domainex Ltd.
Using Direct-to-Biology in a Spectral Shift-PoLiPa Platform to Enable Fast Fragment Follow-Up for A2a Antagonists
Enamine Ltd.
Engineering CRBN and Applying REAL Technology for Rapid Identification of Next Generation CRBN Binders: Design and Activity Evaluation of New Molecular Glue Library and CRBN Ligand-Linker Conjugates
Eurofins Discovery
Integrated Solutions for STAT Inhibition and Targeted Protein Degradation: Enabling Novel Therapies for Cancer, Inflammation and Autoimmune Disease
Fida Biosystems
Characterization of Molecular Glues
Foghorn Therapeutics
Structural and Functional Basis of PU.1-BAF Interaction Reveals a Novel Interface for Targeting Undruggable Transcription Factors
Genovac
Strategic Use of Advanced Technologies and Multiple Host Species to Rapidly Generate Cost-Effective Antibody Candidates
Ginkgo Bioworks
Automated High-Throughput ADME Assays for AI/ML in Drug Discovery
Ginkgo Bioworks
Mapping the Transcriptional Landscape of Drug Responses in Primary Human Cells Using High-Throughput DRUG-seq
Hanmi Pharmaceutical Co Ltd
HM100789, a Novel MAT2A Inhibitor, Demonstrates Antitumor Efficacy Through Synthetic Lethality in MTAP-Deficient Tumors
HitChem
Ligand-Based CRBN Molecular Glue Library: Design, Screening, and Application in Hit Discovery
ICE Bioscience
Building a TPD Discovery Platform for Autoimmune Therapeutics: From Biophysical Screening to In Vivo Validation
ICE Bioscience
Development and Application of an Integrated GPCR-Centric Screening Platform for Anti-Obesity Drug Discovery
Insitro, Inc.
ML-Driven Drug Discovery with DNA-Encoded Libraries
Japan Tobacco, Inc.
A Novel Screening and Machine Learning Method for Cytochrome P450 Induction in Early Drug Discovery Using Advanced Biomimetic Chromatography Targeting the Pregnane X Receptor
Kuano Ltd.
Advanced Quantum Methods for Next-Gen Drug Design: Unlocking Challenging Enzymes and Covalent Reactivity
Mass Dynamics
A Graph Knowledge Base for Multi-Omics Entity Mapping and Integration: Bridging Experimental and External Knowledge Layers
Massachusetts General Hospital
A CRISPR-Based Platform for Characterizing and Rescuing mRNA Splicing Mutations
MaxCyte, Inc.
Accelerating Drug Discovery with Scalable Electroporation and Assay Ready Cells
Medicines Discovery Catapult
An Analytical Platform for Rational Design of Nucleic Acid Therapeutics for Intracellular Delivery
Moffitt Cancer Center & Research Institute
A Computational Chemistry and AI-Driven Framework for Structure-Based Drug Design Informed by Underlying Factors of Mutation-Induced Drug Resistance: A Study of KRAS
Molport
Profiling the Molport In-Stock Compound Database Based on Emerging Drug Discovery Trends
NanoSyrinx Ltd.
NanoSyrinx Platform for Targeted Payload Delivery
National Institutes of Health, National Cancer Institute
Harnessing Ionizing Radiation for Spatiotemporal Control of Induced Covalent Chemistry
National Institutes of Health, National Center for Advancing Translational Sciences
Biochemical Proximity-Based Assay Profiling to Evaluate Cross-Platform Reproducibility in Identifying High-Throughput Screening Hits
Novalix
Identification of a Submicromolar BRD4 PROTAC Degrader from a Moderately Potent DEL Hit: Harnessing the Synergy of DEL and PROTAC Technologies
Nuclera
Functional Membrane Proteins - Ready in 48 Hours
Nuclera
Overcoming the Challenge of Producing Highly Disordered Transcription Factors with eProtein Discovery™
Nuvisan ICB GmbH
Discovery and Characterisation of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo Active KAT6AB Inhibitor
o2h Ltd.
ChameLogK: A Rapid, High-Throughput Assay to Assess Bioavailability of Beyond Rule of Five Compounds
Oncodesign Services
From Genes to Lead Molecules: A Workflow Tuned for Drugging Challenging Therapeutic Targets Using Fragment-Based Drug Discovery
Oxford Biotherapeutics
OGAP®-Diabetes: Proteomics-Based Target Discovery Platform for Type 2 Diabetes Mellitus
Pfizer, Inc.
High-Throughput and Cost-Effective Transcriptomics for Interrogating Compound and CRISPR Perturbations in Cells
Promega Corporation
Automation-Enabled Target Engagement Selectivity Screening of Small Molecule Kinase Inhibitors
Promega Corporation
Innovative Bioluminescence Assays for Monitoring GPCR Dynamics: Advancing Therapeutic Strategies for Metabolic Disease
Promega Corporation
Live Cell NanoBRET®-TE Assays for WRN and Synthetic Lethal Targets in the DNA Damage Response Pathway
Purdue University
Deep Learning Detects Evolutionary Patterns in the Natural Product Space
QIMA Life Sciences
Assessment of a Bi-Specific Macrophage Engager (BiME) in a Co-Injection Tumor Model for Ovarian Cancer
Reaction Biology
Apparent Potency of Small Molecule Inhibitors is Influenced By the Choice of Substrate in LIMK Biochemical In-Vitro Kinase Activity Assays
Reaction Biology
In Vitro Comparison of Kadcyla® and Enhertu® in Breast Cancer with Varying HER2 Expression: Proliferation, Internalization, Bystander Effects and Toxicity
Saint Louis University
Optimization of Nurr1 Agonists in Drug Development for Neurodegenerative Diseases
Saint Louis University
The Lonesome Orphan is Fostered: GCNF Synthetic Modulators Identified
Salipro Biotech AB
Discovery of Novel Therapeutics Against GPCRs, Ion Channels and Transporters with the Salipro® Platform
SARomics Biostructures AB
Structural Insights into Targeting IL-23 with Different Modalities
Selvita / Medicines Discovery Catapult
A Novel Approach to Target Engagement for Drug Discovery
Shinshu University
Cell-Free Preparation of Human Membrane Proteins for Structural Biology and Drug Development
Sygnature Discovery
Hide and Seek: Assessing Druggability and Uncovering Cryptic Pockets
Sygnature Discovery
Seeking New Glues: Toward a Ligase-Agnostic Platform for Molecular Glue Degrader Discovery
Tehran University of Medical Sciences
Development and Characterization of GelMA Hydrogel Containing Temozolomide and YAP siRNA Loaded in Trimethyl Chitosan-Hyaluronate Nanoparticles for Localized Drug Delivery to Glioblastoma Tumors
Transcera
Harnessing Sphingolipid Biology for the Targeted Extracellular Protein Degradation
Trilogie Bioscience
In Vitro Proximity and Ubiquitylation Assays for CRBN, VHL and Emerging Ligases of Interest in TPD
University of Illinois Chicago
Molecular Dynamics Simulations of Metabolite and Peptide Fibrils
University of Minnesota
Design of Allosteric Modulators that Change GPCR G Protein Subtype Selectivity
University of North Texas
Hit Optimization Studies in a Series of 2,5-Substituted Pyrimidine Inhibitors of Slack Potassium Channels
University of Texas at Austin
Discovery of Irreversible Ligands Targeting Functional Tyrosine and Lysine in Living Cells via Activated Sulfonate Esters
University of Texas at Austin
Selective Enhancement of Glycolysis Using a Covalent PFKL Activator
Vaccinex, Inc.
Antibody Discovery for Complex Membrane Antigens
Variational AI
Discovery of Novel Dual EGFR/FGFR1 Inhibitors via AI-Driven Design and Synthesis
Vipergen ApS
DELs in Cells – Integral Membrane Screening
Washington University
Radiometabolic Analysis for Sphingosine-1-Phosphate Receptor 1 (S1PR1) Specific PET-Radiotracers In Vivo
WuXi AppTec
Unleashing the Power of Spectral Shift Technology for Ultra-High-Throughput Binding Assays
X-Chem
Advancing Macrocyclic DNA-Encoded Libraries for Challenging Targets
X-Chem
Exploration, Exploitation and Summarization: Leveraging Thompson Sampling, Deep Data Mining and Pharmacophore Modeling to Access the Wealth of DEL Data for Drug Design Acceleration
Yonsei University
Discovery and Optimization of Kv7.4 Channel (KCNQ4) Selective Activator for Treatment of Hearing Loss